SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, April 9, 2024

Information

Tags:

Complaint, Suite, Certification, Psoriasis, Ethics, Security (finance)

Geotags:

LOS ANGELES, CA, US

Organisation:

SCHALL LAW, VENTYX BIOSCIENCES

Stock Symbol:

NASDAQ:VTYX

Summary

Key Points:

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
The lead clinical product candidate developed by Ventyx, VTX958, was less effective in the treatment of psoriasis than it portrayed to investors.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. (“Ventyx” or “the Company”) (NASDAQ: VTYX) for violations of the federal securities laws.

Investors who purchased the Company's securities pursuant and/or traceable to the Company’s Offering Documents in connection with its initial public offering (“IPO”) conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the ''Class Period''), are encouraged to contact the firm before April 30, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. The lead clinical product candidate developed by Ventyx, VTX958, was less effective in the treatment of psoriasis than it portrayed to investors. The Company overstated the commercial prospects of VTX958. The Company misrepresented its ability to develop and commercialize drug candidates. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Ventyx, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

The Schall Law Firm